Thus, the connecting pathway involving Twist1 expression should be further explored, understanding that Twist1 and other associated downstream regulators could be exploitable in therapeutic designs for EMT→MET reversion, particularly at an early stage of tumour development. The gene discussed is TWIST1; the disease is neoplasm.